BidaskClub upgraded shares of Regenxbio (NASDAQ:RGNX) from a hold rating to a buy rating in a research note issued to investors on Saturday.

RGNX has been the topic of several other research reports. ValuEngine lowered Regenxbio from a hold rating to a sell rating in a report on Tuesday, November 14th. Chardan Capital upped their target price on Regenxbio from $75.00 to $85.00 and gave the company a buy rating in a report on Thursday, November 9th. Barclays assumed coverage on Regenxbio in a report on Wednesday, November 22nd. They issued an overweight rating and a $38.00 target price on the stock. TheStreet lowered Regenxbio from a c rating to a d+ rating in a report on Tuesday, November 28th. Finally, Raymond James Financial reissued a buy rating on shares of Regenxbio in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $40.63.

Shares of Regenxbio (NASDAQ RGNX) opened at $26.60 on Friday. The firm has a market capitalization of $800.43, a price-to-earnings ratio of -9.85 and a beta of -1.30. Regenxbio has a twelve month low of $16.30 and a twelve month high of $36.45.

In related news, SVP Curran Simpson sold 30,000 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $33.03, for a total transaction of $990,900.00. Following the sale, the senior vice president now owns 69,500 shares of the company’s stock, valued at $2,295,585. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $27.33, for a total value of $273,300.00. Following the sale, the insider now directly owns 248,530 shares in the company, valued at approximately $6,792,324.90. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,000 shares of company stock worth $2,879,096. Corporate insiders own 17.00% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of RGNX. State Street Corp boosted its stake in shares of Regenxbio by 178.1% during the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock valued at $17,399,000 after acquiring an additional 564,129 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of Regenxbio by 62.2% during the fourth quarter. Citadel Advisors LLC now owns 987,752 shares of the biotechnology company’s stock valued at $32,843,000 after acquiring an additional 378,612 shares during the last quarter. GMT Capital Corp boosted its stake in shares of Regenxbio by 47.3% during the third quarter. GMT Capital Corp now owns 898,067 shares of the biotechnology company’s stock valued at $29,591,000 after acquiring an additional 288,367 shares during the last quarter. RTW Investments LP boosted its stake in shares of Regenxbio by 20.9% during the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock valued at $50,710,000 after acquiring an additional 266,235 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Regenxbio by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock valued at $21,379,000 after acquiring an additional 100,944 shares during the last quarter. 68.66% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Regenxbio (RGNX) Upgraded at BidaskClub” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/regenxbio-rgnx-upgraded-at-bidaskclub.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.